Merck HIV pill could cost under $5 per patient yearly
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers said Merck's experimental HIV prevention pill MK 8527 could be mass-produced for less than $5 per patient per year, arguing the low cost should make it easier for Merck to license the drug to low- and middle-income countries.
- MK 8527 is currently in a pair of late-stage clinical trials testing whether the medicine can lower HIV transmission among people at high risk of infection.
- Clinical trials for MK 8527 are expected to read out in the latter half of 2027, according to postings on ClinicalTrials.gov.
- Merck released mid-stage results last summer showing the pill was safe and effective, and could provide protection against infection — a form of PrEP — within 24 hours of being taken.
- Merck noted that MK 8527 works through a novel mechanism, distinguishing it from existing HIV prevention options.
Why it matters: If MK 8527 proves effective in late-stage trials expected by late 2027, a sub-$5 annual price tag would remove a major barrier to deploying PrEP at scale in low- and middle-income countries, where cost has historically limited access to HIV prevention. The researchers' framing puts pressure on Merck to license broadly, potentially reshaping how new HIV prevention tools reach the populations most at risk.
